Portfolio Sync Solutions
Streamline your investment strategy with our portfolio synchronization tools. Seamlessly manage and track your holdings across platforms for enhanced
GET STARTEDPropanc Biopharma Inc Earnings History by Quarter
| Date | Quarter | Consensus Estimate | Reported EPS | Beat/Miss | Revenue Estimate | Actual Revenue |
|---|---|---|---|---|---|---|
| 05/14/2026 | Q3 2026 | N/A | -$7.00 | N/A | N/A | $0 |
| 02/17/2026 | Q2 2026 | N/A | -$7.50 | N/A | N/A | $0 |
| 11/14/2025 | Q1 2026 | N/A | -$9.75 | N/A | N/A | $0 |
| 09/29/2025 | Q4 2025 | N/A | -$8.75 | N/A | N/A | $0 |
| 05/15/2025 | Q3 2025 | N/A | -$312.50 | N/A | N/A | $0 |
| 02/14/2025 | Q2 2025 | N/A | -$805.50 | N/A | N/A | $0 |
| 11/14/2024 | Q1 2025 | N/A | -$7,195.50 | N/A | N/A | $0 |
| 09/30/2024 | Q4 2024 | N/A | -$2,398.75 | N/A | N/A | $0 |
| 05/15/2024 | Q3 2024 | N/A | -$7,419.25 | N/A | N/A | $0 |
| 02/20/2024 | Q2 2024 | N/A | -$25,704.75 | N/A | N/A | $0 |
| 11/14/2023 | Q1 2024 | N/A | -$1.12 | N/A | N/A | $0 |
| 09/28/2023 | Q4 2023 | N/A | -$3.25 | N/A | N/A | $0 |
| 05/15/2023 | Q3 2023 | N/A | -$10.50 | N/A | N/A | $0 |
| 02/09/2023 | Q2 2023 | N/A | -$13.25 | N/A | N/A | $0 |
| 11/14/2022 | Q1 2023 | N/A | -$53.25 | N/A | N/A | $0 |
| 09/28/2022 | Q4 2022 | N/A | -$131.50 | N/A | N/A | $0 |
| 05/16/2022 | Q3 2022 | N/A | -$263.75 | N/A | N/A | $0 |
| 02/14/2022 | Q2 2022 | N/A | -$452.25 | N/A | N/A | $0 |
| 11/12/2021 | Q1 2022 | N/A | -$557.75 | N/A | N/A | $0 |
| 09/28/2021 | Q4 2021 | N/A | -$2,082.50 | N/A | N/A | $0 |
Explore Related Stocks for Market Trends
Explore our related stocks for the latest market trends and stock news to stay informed and make better decisions.
Propanc Biopharma Inc Earnings: FAQ's
The conference call for Propanc Biopharma Inc's latest earnings report can be listened to online.
The conference call transcript for Propanc Biopharma Inc's latest earnings report can be read online.
Propanc Biopharma Inc (:PPCB) has a recorded net income of $-58,923,300.Propanc Biopharma Inc has generated $-371.25 earnings per share over the last four quarters.
Propanc Biopharma Inc (:PPCB) has a price-to-earnings ratio of -0.04 and price/earnings-to-growth ratio is -0.